NextCure (NASDAQ:NXTC) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of NextCure (NASDAQ:NXTC) in a research note released on Friday, Benzinga reports. They currently have a $8.00 price target on the stock.

Separately, Needham & Company LLC restated a buy rating and issued a $4.00 price target on shares of NextCure in a research note on Wednesday, March 20th.

NextCure Stock Up 7.8 %

NextCure stock traded up $0.12 during trading hours on Friday, hitting $1.65. The stock had a trading volume of 129,103 shares, compared to its average volume of 231,066. The stock’s 50-day moving average price is $1.72 and its 200-day moving average price is $1.40. The stock has a market capitalization of $46.15 million, a P/E ratio of -0.75 and a beta of 0.54. NextCure has a 12-month low of $0.98 and a 12-month high of $2.57.

NextCure (NASDAQ:NXTC) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.02. On average, research analysts expect that NextCure will post -1.65 EPS for the current fiscal year.

Institutional Trading of NextCure

A number of large investors have recently made changes to their positions in the stock. Marquette Asset Management LLC purchased a new stake in NextCure in the fourth quarter worth approximately $66,000. Acuitas Investments LLC lifted its holdings in shares of NextCure by 30.0% during the 4th quarter. Acuitas Investments LLC now owns 372,799 shares of the company’s stock valued at $425,000 after buying an additional 85,982 shares during the period. Assenagon Asset Management S.A. bought a new position in shares of NextCure during the 1st quarter valued at $952,000. Finally, Cable Car Capital LLC purchased a new position in shares of NextCure in the 4th quarter worth $702,000. 42.65% of the stock is currently owned by institutional investors.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.